BioNTech SE

BioNTech SE is a global next generation immunotherapy company founded in 2008 and headquartered in Germany. With a vision to harness the power of the immune system for developing novel therapies against cancer and infectious diseases, BioNTech boasts a team of around 6,100 pioneers utilizing computational discovery and therapeutic drug platforms for rapid development of novel biopharmaceuticals. The company's broad portfolio of product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies, antibody-drug conjugate (ADC) therapeutics, and small molecules. With deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech is developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. For further information, visit www.BioNTech.com.